Federal Official Gazette
ADMINISTRATIVE RESOLUTION ANS No. 89, OF MAY 18, 2026
Provides for the initiation, organization and processing of the Special Accounts Audit (Tomada de Contas Especial – TCE) within ANS, as well as its referral to the Federal Court of Accounts (Tribunal de Contas da União – TCU).
ANS news
New prostate cancer drug is added to the ANS List (Rol)
This is the drug Olaparib as monotherapy, for the treatment of adult patients with metastatic prostate cancer, in specific cases set out by ANS, with a mutation in the BRCA1 and/or BRCA2 genes, whose disease has progressed after prior treatment with a new hormonal agent.
ANS also approved a change in the coverage rules for Nirsevimab, a drug used in the immunoprophylactic therapy of Respiratory Syncytial Virus (RSV), one of the main causes of respiratory infections in babies.
Open public consultations
- CP 172. Aims to receive contributions on the proposed updates to the List of Health Procedures and Events (Rol). Deadline:Gregorian dates May 13, 2026 to Jun 2, 2026.
- CP 170. Update of the regulation of the relationship between private health care plan operators and health care service providers. Extension: Apr 1, 2026 to Jul 3, 2026.
Scheduled public hearings
- New: AP 66. Collection of contributions on the preliminary recommendation of non-incorporation for the following technologies: UAT 188 – Bimekizumab for the treatment of moderate to severe active hidradenitis suppurativa in adults who failed, were intolerant to or had a contraindication to systemic antibiotic therapy; and UAT 198 – Capivasertib for the treatment of locally advanced or metastatic breast cancer, HR+ and HER2-, with one or more alterations in PIK3CA/AKT1/PTEN. Date: May 22, 2026, from 9:30 a.m. to 12:30 p.m.
Open public calls for input
There is no open public call for input.
Open public calls
No updates.
Other news
CFM opinion clarifies that denervation and rhizotomy are distinct procedures
Source: news.cremerj.org.br · read the full article
Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.